Synonyms: BAL-9141 | BAL9141 | BAL9141-000 | BAL9141000 | Ro-63-9141 | Ro-639141 | Zeftera® | Zevtera®
ceftobiprole is an approved drug (UK (2013), FDA (2024))
Compound class:
Synthetic organic
Comment: Ceftobiprole is a clinical stage, broad-spectrum, fifth-generation, pyrrolidinone cephalosporin antibacterial [3]. It was developed as a treatment for hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP), in particular those infections caused by methicillin-resistant Staphylococcus aureus (MRSA). In clinical trials ceftobiprole is administered by intravenous infusion as the water-soluble prodrug ceftobiprole medocaril (BAL5788; PubChem CID 135413544).
|
|
References |
1. Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, Sánchez AS, Zhou X, Saulay M et al.. (2014)
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis, 59 (1): 51-61. [PMID:24723282] |
2. EMA.
Zeftera (previously Zevtera). Accessed on 30/04/2020. Modified on 30/04/2020. European Medicines Agency, https://www.ema.europa.eu/en/medicines/human/EPAR/zeftera-previously-zevtera |
3. Morosini MI, Díez-Aguilar M, Cantón R. (2019)
Mechanisms of action and antimicrobial activity of ceftobiprole. Rev Esp Quimioter, 32 Suppl 3: 3-10. [PMID:31364335] |